Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Reinvestment Rate

Latest as of December 2024: 3.81x

Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Reinvestment Rate of 3.81x as of December 2024, reinvesting CN¥1.27 Billion (capex CN¥540.28 Million plus investments CN¥-726.77 Million) from operating cash flow of CN¥332.41 Million. See Aurisco Pharmaceutical Co Ltd (605116) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

3.81x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥1.27 Billion
Capex + Investments

Operating Cash Flow

CN¥332.41 Million
CNY

Capital Expenditures

CN¥540.28 Million
CNY

Aurisco Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Aurisco Pharmaceutical Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Aurisco Pharmaceutical Co Ltd.

Annual Cash Flow Reinvestment Rate for Aurisco Pharmaceutical Co Ltd (2017–2024)

Year-by-year capital reinvestment analysis for Aurisco Pharmaceutical Co Ltd. See financial flexibility index of Aurisco Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 3.81x CN¥1.27 Billion CN¥332.41 Million CN¥540.28 Million ▲ +119.1%
2023 1.74x CN¥670.75 Million CN¥385.61 Million CN¥305.48 Million ▼ -38.8%
2022 2.84x CN¥473.01 Million CN¥166.41 Million CN¥216.23 Million ▲ +11.7%
2021 2.54x CN¥512.96 Million CN¥201.57 Million CN¥250.61 Million ▲ +72.8%
2020 1.47x CN¥315.81 Million CN¥214.48 Million CN¥158.80 Million ▲ +71.4%
2019 0.86x CN¥154.57 Million CN¥179.90 Million CN¥72.47 Million ▲ +0.2%
2018 0.86x CN¥94.14 Million CN¥109.77 Million CN¥94.14 Million ▼ -5.1%
2017 0.90x CN¥106.60 Million CN¥117.91 Million CN¥106.60 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow